Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
Recruiting · NCT06634979 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Selective lymph node dissection
What this trial is about
The study investigated the efficacy and safety of a selective lymph node strategy (no lower mediastinal lymph node dissection for upper lobe tumors and no upper mediastinal lymph node dissection for lower lobe tumors) in patients with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter cT1N0M0 infiltrating NSCLC, aiming to more accurately assess the prognosis of the selective lymph node dissection strategy for nodes with 0.5 \< CTR \< 1 and ≤ 2 cm in diameter.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Volunteer to participate in a clinical study and be willing to follow and have the ability to complete all trial procedures;
- Age 18-80 years at time of signing informed consent (including threshold);
- ECOG score 0 or 1;
- No previous surgery for lung cancer;
- Intraoperative or postoperative pathologically confirmed non-small cell lung cancer;
- Single pulmonary nodule with mixed ground glass on CT, or multiple pulmonary nodules but the main lesion is the above nodules;
- The proportion of solid components of the nodule is between 0.5 and 1, and the total size of the nodule is less than or equal to 2 cm;
- Patients with clinical stage T1N0M0 surgically resectable;
- Primary treatment without radiotherapy or chemotherapy.
Exclusion criteria
- T1N0M0 with a clinical stage other than 0.5 \< CTR \< 1 and a diameter of ≤ 2 cm;
- Inability to perform complete surgical resection;
- cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer;
- Previous surgery for lung cancer;
- Patients who have received radiotherapy or chemotherapy for non-primary treatment.
Where it is running
1 location listed.
- Fudan University Shanghai Cancer Center - Shanghai, China